vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and INSTEEL INDUSTRIES INC (IIIN). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $159.9M, roughly 1.8× INSTEEL INDUSTRIES INC). INSTEEL INDUSTRIES INC runs the higher net margin — 4.7% vs -45.7%, a 50.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 23.3%). INSTEEL INDUSTRIES INC produced more free cash flow last quarter ($-2.2M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 12.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.
GH vs IIIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $159.9M |
| Net Profit | $-128.5M | $7.6M |
| Gross Margin | 64.6% | 11.3% |
| Operating Margin | -43.0% | 6.0% |
| Net Margin | -45.7% | 4.7% |
| Revenue YoY | 39.4% | 23.3% |
| Net Profit YoY | -15.8% | 602.4% |
| EPS (diluted) | $-1.01 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $159.9M | ||
| Q3 25 | $265.2M | $177.4M | ||
| Q2 25 | $232.1M | $179.9M | ||
| Q1 25 | $203.5M | $160.7M | ||
| Q4 24 | $201.8M | $129.7M | ||
| Q3 24 | $191.5M | $134.3M | ||
| Q2 24 | $177.2M | $145.8M | ||
| Q1 24 | $168.5M | $127.4M |
| Q4 25 | $-128.5M | $7.6M | ||
| Q3 25 | $-92.7M | $14.6M | ||
| Q2 25 | $-99.9M | $15.2M | ||
| Q1 25 | $-95.2M | $10.2M | ||
| Q4 24 | $-111.0M | $1.1M | ||
| Q3 24 | $-107.8M | $4.7M | ||
| Q2 24 | $-102.6M | $6.6M | ||
| Q1 24 | $-115.0M | $6.9M |
| Q4 25 | 64.6% | 11.3% | ||
| Q3 25 | 64.7% | 16.1% | ||
| Q2 25 | 65.0% | 17.1% | ||
| Q1 25 | 63.3% | 15.3% | ||
| Q4 24 | 61.6% | 7.3% | ||
| Q3 24 | 61.1% | 9.1% | ||
| Q2 24 | 59.1% | 10.6% | ||
| Q1 24 | 61.2% | 12.3% |
| Q4 25 | -43.0% | 6.0% | ||
| Q3 25 | -37.3% | 10.8% | ||
| Q2 25 | -45.9% | 11.0% | ||
| Q1 25 | -54.6% | 8.3% | ||
| Q4 24 | -62.4% | 1.1% | ||
| Q3 24 | -61.3% | 4.5% | ||
| Q2 24 | -56.8% | 6.0% | ||
| Q1 24 | -59.2% | 7.0% |
| Q4 25 | -45.7% | 4.7% | ||
| Q3 25 | -35.0% | 8.2% | ||
| Q2 25 | -43.0% | 8.4% | ||
| Q1 25 | -46.8% | 6.4% | ||
| Q4 24 | -55.0% | 0.8% | ||
| Q3 24 | -56.3% | 3.5% | ||
| Q2 24 | -57.9% | 4.5% | ||
| Q1 24 | -68.2% | 5.4% |
| Q4 25 | $-1.01 | $0.39 | ||
| Q3 25 | $-0.74 | $0.74 | ||
| Q2 25 | $-0.80 | $0.78 | ||
| Q1 25 | $-0.77 | $0.52 | ||
| Q4 24 | $-0.90 | $0.06 | ||
| Q3 24 | $-0.88 | $0.24 | ||
| Q2 24 | $-0.84 | $0.34 | ||
| Q1 24 | $-0.94 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $15.6M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $358.8M |
| Total Assets | $2.0B | $456.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $15.6M | ||
| Q3 25 | $580.0M | $38.6M | ||
| Q2 25 | $629.1M | $53.7M | ||
| Q1 25 | $698.6M | $28.4M | ||
| Q4 24 | $525.5M | $36.0M | ||
| Q3 24 | $585.0M | $111.5M | ||
| Q2 24 | $933.7M | $97.7M | ||
| Q1 24 | $1.0B | $83.9M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $358.8M | ||
| Q3 25 | $-354.5M | $371.5M | ||
| Q2 25 | $-305.5M | $356.2M | ||
| Q1 25 | $-250.8M | $341.4M | ||
| Q4 24 | $-139.6M | $331.6M | ||
| Q3 24 | $-60.1M | $350.9M | ||
| Q2 24 | $-1.6M | $346.0M | ||
| Q1 24 | $68.3M | $340.6M |
| Q4 25 | $2.0B | $456.1M | ||
| Q3 25 | $1.3B | $462.6M | ||
| Q2 25 | $1.3B | $471.9M | ||
| Q1 25 | $1.3B | $421.9M | ||
| Q4 24 | $1.5B | $404.7M | ||
| Q3 24 | $1.5B | $422.6M | ||
| Q2 24 | $1.6B | $414.6M | ||
| Q1 24 | $1.7B | $397.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-701.0K |
| Free Cash FlowOCF − Capex | $-54.2M | $-2.2M |
| FCF MarginFCF / Revenue | -19.3% | -1.4% |
| Capex IntensityCapex / Revenue | 9.9% | 0.9% |
| Cash ConversionOCF / Net Profit | — | -0.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $439.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-701.0K | ||
| Q3 25 | $-35.4M | $-17.0M | ||
| Q2 25 | $-60.3M | $28.5M | ||
| Q1 25 | $-62.7M | $-3.3M | ||
| Q4 24 | $-64.5M | $19.0M | ||
| Q3 24 | $-51.1M | $16.2M | ||
| Q2 24 | $-94.0M | $18.8M | ||
| Q1 24 | $-30.3M | $1.4M |
| Q4 25 | $-54.2M | $-2.2M | ||
| Q3 25 | $-45.8M | $-18.7M | ||
| Q2 25 | $-65.9M | $26.9M | ||
| Q1 25 | $-67.1M | $-5.5M | ||
| Q4 24 | $-83.4M | $16.3M | ||
| Q3 24 | $-55.3M | $14.5M | ||
| Q2 24 | $-99.1M | $15.5M | ||
| Q1 24 | $-37.2M | $-580.0K |
| Q4 25 | -19.3% | -1.4% | ||
| Q3 25 | -17.3% | -10.6% | ||
| Q2 25 | -28.4% | 15.0% | ||
| Q1 25 | -33.0% | -3.5% | ||
| Q4 24 | -41.3% | 12.6% | ||
| Q3 24 | -28.9% | 10.8% | ||
| Q2 24 | -55.9% | 10.7% | ||
| Q1 24 | -22.1% | -0.5% |
| Q4 25 | 9.9% | 0.9% | ||
| Q3 25 | 3.9% | 1.0% | ||
| Q2 25 | 2.4% | 0.9% | ||
| Q1 25 | 2.2% | 1.4% | ||
| Q4 24 | 9.4% | 2.1% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 2.9% | 2.2% | ||
| Q1 24 | 4.1% | 1.5% |
| Q4 25 | — | -0.09× | ||
| Q3 25 | — | -1.17× | ||
| Q2 25 | — | 1.88× | ||
| Q1 25 | — | -0.32× | ||
| Q4 24 | — | 17.56× | ||
| Q3 24 | — | 3.48× | ||
| Q2 24 | — | 2.86× | ||
| Q1 24 | — | 0.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
IIIN
| Welded Wire Reinforcement | $108.4M | 68% |
| PC Strand | $51.6M | 32% |
